Eli Lilly issues data sharing ultimatum to 340B hospitals

Eli Lilly Issues Data Sharing Ultimatum to 340B Hospitals

Eli Lilly has given more than 1,000 hospitals a five-day deadline to submit claims-level data or lose 340B discounts entirely. The move marks the most aggressive enforcement action yet by a major manufacturer against covered entities, escalating a standoff that could reshape how billions of dollars in safety-net drug discounts flow through the U.S. healthcare system.

Key Takeaways

• Lilly set a hard deadline for over 1,000 340B covered entities to provide claims data verifying they are not receiving duplicate discounts through contract pharmacies.
• Hospitals that fail to comply risk losing all 340B pricing on Lilly products, a move that could shift significant costs onto safety-net providers.
• The American Hospital Association has formally urged HRSA to intervene, calling the policy unworkable and pressing Lilly to adopt a neutral data-sharing mechanism instead.
• Novo Nordisk and Exelixis are pursuing similar data-reporting requirements, signaling a broader industry effort to tighten 340B oversight.
• The dispute centers on whether manufacturers can unilaterally impose conditions on 340B access, a question that may ultimately require regulatory or legal resolution.

What Happened?

In a January 15 notice to covered entities, Eli Lilly announced it will require hospitals and community health centers—including their in-house pharmacies—to submit claims-level data for every dispense made under the 340B program. The drugmaker said certain hospitals had refused to provide documentation proving they were not obtaining duplicate discounts, a practice known as "double-dipping," in which a manufacturer effectively provides both a 340B discount and a Medicaid rebate on the same drug unit.

Lilly framed the data push as a compliance necessity. If a covered entity fails to deliver timely, complete, and accurate data for all 340B dispenses, the company said it may cancel 340B pricing for that entity entirely. The five-day compliance window left hospitals scrambling to assess whether their pharmacy systems could generate and transmit the required detail on the specified timeline.

The American Hospital Association responded quickly, urging Lilly to drop the policy and instead collaborate on a functional, neutral data-sharing framework. In a letter to HRSA, the AHA asked the agency to prohibit manufacturers from unilaterally altering 340B participation terms through claims-reporting mandates. Hospital groups argue that the requirements are at best prohibitively costly and at worst technically unworkable for many 340B entities.

Why Is Lilly Taking This Step Now?

The ultimatum reflects a years-long escalation in the 340B contract-pharmacy dispute. Since 2021, over a dozen drugmakers have restricted 340B pricing at contract pharmacies through third-party data platforms, often requiring covered entities to submit claims data to verify eligibility. But Lilly's hard deadline and explicit threat to revoke discounts entirely raises the stakes considerably, shifting from a passive data-collection posture to an active enforcement mechanism with immediate financial consequences for noncompliant hospitals.

At the core of the dispute is the duplicate-discount problem. Federal law prohibits manufacturers from providing both a 340B discount and a Medicaid rebate on the same drug unit. As contract-pharmacy arrangements have expanded—with some hospitals dispensing 340B drugs through hundreds of retail pharmacy locations—manufacturers argue they lack the visibility needed to prevent violations. Lilly's position is that without claims-level data, it cannot verify compliance and is therefore entitled to withhold discounts.

Hospitals counter that the 340B statute imposes a unilateral obligation on manufacturers to offer discounted prices, and that adding data-reporting conditions amounts to an unauthorized modification of program terms. The legal question remains unresolved, and HRSA has not issued definitive guidance on whether manufacturers may attach such conditions to 340B pricing.

What Does This Mean for Pharma Strategy and Market Access?

For analysts and business development teams, Lilly's ultimatum signals that manufacturer use over 340B participation is entering a new phase. The immediate strategic impact is twofold. First, it forces hospital systems to evaluate whether their pharmacy infrastructure can meet manufacturer-specific data requirements—a capability that varies widely across large academic medical centers and small rural critical-access hospitals. Second, it creates a competitive dynamic: if Lilly successfully enforces compliance without significant regulatory pushback, other manufacturers are likely to follow.

Novo Nordisk and Exelixis have already instituted similar data-reporting requirements, suggesting a coordinated industry posture rather than an isolated action. For BD teams evaluating partnerships or distribution arrangements with 340B entities, the compliance burden is now a material variable. Hospitals that cannot meet data-reporting timelines may face margin compression, which could affect their willingness to participate in outcomes-based contracts or risk-sharing agreements with manufacturers. The dispute also introduces a new dimension of counterparty risk into manufacturer-provider negotiations.

From a regulatory standpoint, the central question is whether HRSA has the authority to prevent manufacturers from imposing conditions on 340B pricing. The program statute requires manufacturers to offer discounted prices to covered entities but does not explicitly address data-sharing obligations. Until HRSA or the courts resolve the question, manufacturers hold significant use through their ability to set the terms of data access.

How Are Hospital Groups Responding?

The AHA has taken the most visible stance, formally urging HRSA to prohibit manufacturers from unilaterally imposing claims-reporting mandates. The association has proposed that any data-sharing framework be developed collaboratively through a neutral mechanism rather than dictated by individual manufacturers. In its letter to HRSA, the AHA argued that Lilly's policy would be "prohibitively costly for 340B hospitals" and potentially "unworkable" for entities lacking sophisticated pharmacy data systems.

Individual hospital systems have echoed these concerns, noting that the five-day timeline is insufficient to extract, format, and transmit claims data across multiple pharmacy locations and dispensing platforms. Some have pointed out that the data requirements go beyond what is necessary to verify 340B eligibility, effectively demanding proprietary claims information that manufacturers could use for competitive intelligence purposes.

Provider advocates have also raised equity concerns. Safety-net hospitals serving low-income populations rely heavily on 340B savings to fund uncompensated care, community health programs, and medication access initiatives. Forcing these entities to absorb higher drug costs or invest heavily in data infrastructure could undermine the program's core mission.

What Happens Next?

The immediate watchpoint is whether covered entities comply with Lilly's deadline and whether the company follows through on its threat to revoke discounts. Any enforcement action will likely draw a rapid regulatory and legal response from hospital groups. HRSA's position on manufacturer-imposed data requirements will determine whether this becomes a precedent or a flashpoint that forces legislative clarification of the 340B statute.

Stakeholders should also monitor whether Congress takes up 340B reform proposals that address the data-sharing question directly. Several legislative efforts have circulated in recent sessions, and the current dispute adds urgency to those discussions. The outcome will shape not only the 340B program's future but also the broader balance of power between manufacturers and safety-net providers in drug pricing negotiations.

Frequently Asked Questions

Related coverage

• Eli Lilly's 340B Data Mandate: A New Tactic in Pharma's Discount Program Battle
• ASCO 2026 Preview: Key Data and Trends in Cancer Research
• This Week in Breast Cancer: Camizestrant Delay, Bria-IMT Data, Recurrence Test